Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 5/20 | 0.64 |
| ▸ | BRAF | P15056 | 10/20 | 0.62 |
| ▸ | EGFR | P00533 | 7/20 | 0.62 |
| ▸ | CSF1R | P07333 | 3/20 | 0.62 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 4/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13813463 | 0.89 | KIT (0.51) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL12851923 | 0.85 | ABL1 (0.75) | KITKDRABL1 | |
| SCHEMBL13772031 | 0.85 | BRAF (0.79) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL13771723 | 0.83 | RET (0.83) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL31620780 | 0.83 | KIT (0.64) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL13772005 | 0.83 | BRAF (0.69) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL13772100 | 0.82 | RET (0.66) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL4905442 | 0.82 | KIT (0.67) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL13772103 | 0.82 | RET (0.65) | KITBRAFEGFRCSF1RRET | |
| SCHEMBL28806373 | 0.81 | BRAF (0.75) | KITBRAFEGFRCSF1RRET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | KIT 813/4885BRAF 2370/4885EGFR 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.